DK95291A - Rekombinante dna-molekyler - Google Patents

Rekombinante dna-molekyler Download PDF

Info

Publication number
DK95291A
DK95291A DK095291A DK95291A DK95291A DK 95291 A DK95291 A DK 95291A DK 095291 A DK095291 A DK 095291A DK 95291 A DK95291 A DK 95291A DK 95291 A DK95291 A DK 95291A
Authority
DK
Denmark
Prior art keywords
dna molecules
polypeptides
carrier protein
human
processes
Prior art date
Application number
DK095291A
Other languages
Danish (da)
English (en)
Other versions
DK95291D0 (da
Inventor
Emerald Martin Spencer
Carol Talkingtonverser
Original Assignee
Biogrowth Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23115154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK95291(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogrowth Inc filed Critical Biogrowth Inc
Publication of DK95291D0 publication Critical patent/DK95291D0/da
Publication of DK95291A publication Critical patent/DK95291A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK095291A 1988-12-22 1991-05-21 Rekombinante dna-molekyler DK95291A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29025088A 1988-12-22 1988-12-22
PCT/US1989/005791 WO1990006950A1 (en) 1988-12-22 1989-12-21 Recombinant dna molecules, hosts, processes and human somatomedin carrier protein-like polypeptides

Publications (2)

Publication Number Publication Date
DK95291D0 DK95291D0 (da) 1991-05-21
DK95291A true DK95291A (da) 1991-08-16

Family

ID=23115154

Family Applications (1)

Application Number Title Priority Date Filing Date
DK095291A DK95291A (da) 1988-12-22 1991-05-21 Rekombinante dna-molekyler

Country Status (14)

Country Link
EP (2) EP0451194B1 (de)
JP (2) JPH04503352A (de)
KR (1) KR910700261A (de)
AT (1) ATE155793T1 (de)
AU (1) AU4836890A (de)
CA (1) CA2006322C (de)
DE (1) DE68928203T2 (de)
DK (1) DK95291A (de)
ES (1) ES2107422T3 (de)
GR (1) GR3025094T3 (de)
HK (1) HK1000826A1 (de)
IL (1) IL92816A0 (de)
WO (1) WO1990006950A1 (de)
ZA (1) ZA899832B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5198340A (en) * 1991-01-17 1993-03-30 Genentech, Inc. Assay for free igf-i, igf-ii, and gh levels in body fluids
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5643867A (en) * 1992-08-26 1997-07-01 Celtrix Pharmaceuticals, Inc. Method for treating catabolic conditions
JPH10512235A (ja) * 1994-07-20 1998-11-24 セルトリックス ファーマシューティカルズ，インコーポレイテッド 骨形成の促進および骨再造形の調節のためのｉｇｆ／ｉｇｆｂｐ複合体
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
WO2000040612A1 (en) 1999-01-06 2000-07-13 Genentech, Inc. Insulin-like growth factor (igf) i mutant variants
DK1141014T3 (da) 1999-01-06 2005-04-11 Genentech Inc Insulinlignende vækstfaktor (IGF) i mutantvariant
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
EP1401476A4 (de) 2001-03-14 2006-03-08 Genentech Inc Igf-antagonistenpeptide
ES2527871T3 (es) 2003-05-01 2015-02-02 Imclone Llc Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana
ATE536186T1 (de) 2003-09-12 2011-12-15 Tercica Inc Verfahren zur behandlung von igf-1 (insulin-like growth factor 1)-mangel
EP1670822A2 (de) 2003-10-03 2006-06-21 Genentech, Inc. Igf-bindende proteine
JP2009501141A (ja) 2005-06-17 2009-01-15 イムクローン システムズ インコーポレイテッド 転移性骨癌の治療のための受容体アンタゴニスト
JP5198289B2 (ja) 2006-02-03 2013-05-15 イムクローン・リミテッド・ライアビリティ・カンパニー 前立腺癌の治療用アジュバントとしてのｉｇｆ−ｉｒアンタゴニスト
EA202090705A1 (ru) 2017-09-11 2020-06-11 Шайр Хьюман Дженетик Терапиз, Инк. Способы и композиции, предназначенные для лечения хронических заболеваний легких
CN117098547A (zh) 2020-10-19 2023-11-21 奥克希尔生物有限公司 适用于新生儿的组合物
WO2023139115A1 (en) 2022-01-19 2023-07-27 Oak Hill Bio Limited Compositions and methods for reducing oxidation of igf‐1/igfbp
WO2023242440A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants
WO2023242442A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Method of maturing/differentiating neurons and/or modulating the vagus nerve
WO2023242439A1 (en) 2022-06-17 2023-12-21 Oak Hill Bio Limited Vascular stabilisation (preterm infants)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4738921A (en) * 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4861757A (en) * 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
US4885163A (en) * 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
US5057417A (en) * 1987-06-12 1991-10-15 Genentech, Inc. Compositions and methods for the synthesis of growth hormone receptor and growth hormone binding protein
ES2017122A6 (es) * 1988-03-17 1991-01-01 Nordisk Gentofte Ans Procedimiento de preparacion de proteina de ligado de heparina.
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
EP0418230B1 (de) * 1988-04-12 1995-12-27 Amgen Boulder Inc. Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors

Also Published As

Publication number Publication date
ATE155793T1 (de) 1997-08-15
ES2107422T3 (es) 1997-12-01
GR3025094T3 (en) 1998-01-30
HK1000826A1 (en) 1998-05-01
DK95291D0 (da) 1991-05-21
CA2006322C (en) 2000-08-01
CA2006322A1 (en) 1990-06-22
ZA899832B (en) 1990-10-31
WO1990006950A1 (en) 1990-06-28
DE68928203T2 (de) 1998-01-15
EP0375438A3 (de) 1992-03-25
KR910700261A (ko) 1991-03-14
AU4836890A (en) 1990-07-10
EP0451194A1 (de) 1991-10-16
DE68928203D1 (de) 1997-09-04
JPH11236400A (ja) 1999-08-31
IL92816A0 (en) 1990-09-17
JPH04503352A (ja) 1992-06-18
EP0375438A2 (de) 1990-06-27
EP0451194A4 (en) 1992-09-02
EP0451194B1 (de) 1997-07-23

Similar Documents

Publication Publication Date Title
DK95291A (da) Rekombinante dna-molekyler
DK677688D0 (da) Humane somatomedinbaererproteinunderenheder og fremgangsmaade til fremstilling af saadanne
DE262192T1 (de) Verfahren und mittel zur herstellung eines proteins mit dergleichen igg-spezifizitaet wie protein g.
FI102768B1 (fi) Hybridi-DNA-molekyyli ja menetelmä fibronektiiniä sitovan proteiinin valmistamiseksi
DE721983T1 (de) Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
FI103892B1 (fi) Rekombinantti-DNA-molekyyli, joka koodaa polypeptidiä/proteiinia, jolla on oleellisesti vaskulaaristen antikoaguloivien proteiinien biologiset ominaisuudet sekä niiden valmistus
DE3855084D1 (de) Herstellung und Reinigung eines Proteins, das mit einem Bindungsprotein fusioniert ist
NO177570C (no) Fremgangsmåte ved fremstilling av peptider med fibronektinbindende egenskaper, mikroorganisme og DNA-sekvens som koder for peptider med fibronektinbindende egenskaper
EP0546074A4 (en) Genetic material encoding igfbp-5
FI921600A0 (fi) Bjoerkpollenallergen p14 foer diagnos och behandling av allergiska sjukdomar.
PT98804A (pt) Processo de preparacao de igfbp-4 ou um fragmento da mesma
EP0261403A3 (de) Polypeptide des Rhinovirusstammes HRV89 sowie die hierfür codierenden DNA-Moleküle
SE8801723D0 (sv) Fibronectin binding protein as well as its preparation
WO1995008628A3 (en) Nucleic acids encoding merosin, merosin fragments and uses thereof
DK27097A (da) Minactivin og fremgangsmåde til fremstilling deraf
IL78278A0 (en) Process for the production of polypeptides,dna sequence encoding desired polypeptide human somatomedin c polypeptide and recombinant dna molecules
Spencer et al. Uses for antibodies which bind to human somatomedin carrier protein subunits
MX9504057A (es) Proteina que tiene actividad tpo.